LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO Sells $2,331,878.10 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the transaction, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

LeMaitre Vascular Price Performance

Shares of LMAT stock traded up $0.71 during trading hours on Tuesday, reaching $87.02. 259,631 shares of the company were exchanged, compared to its average volume of 123,074. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 57.63, a P/E/G ratio of 2.62 and a beta of 0.89. The stock’s fifty day moving average is $80.31 and its two-hundred day moving average is $69.01. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $88.36.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.05. The firm had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.27 EPS. On average, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.74%. The ex-dividend date was Wednesday, May 15th. LeMaitre Vascular’s payout ratio is 42.38%.

Analyst Ratings Changes

Several research firms have recently weighed in on LMAT. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and upped their price objective for the company from $59.00 to $75.00 in a research note on Friday, April 26th. JMP Securities boosted their target price on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research note on Friday, May 3rd. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, June 22nd. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. Finally, Barrington Research upped their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.57.

Institutional Trading of LeMaitre Vascular

A number of institutional investors and hedge funds have recently modified their holdings of LMAT. Vanguard Group Inc. boosted its holdings in shares of LeMaitre Vascular by 2.3% in the third quarter. Vanguard Group Inc. now owns 1,510,567 shares of the medical instruments supplier’s stock valued at $82,296,000 after buying an additional 33,500 shares during the period. Exchange Traded Concepts LLC increased its stake in LeMaitre Vascular by 0.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock valued at $1,343,000 after buying an additional 187 shares during the last quarter. Ausbil Investment Management Ltd increased its stake in LeMaitre Vascular by 28.3% in the 4th quarter. Ausbil Investment Management Ltd now owns 17,025 shares of the medical instruments supplier’s stock valued at $966,000 after buying an additional 3,753 shares during the last quarter. Raymond James & Associates lifted its position in LeMaitre Vascular by 13.3% during the 4th quarter. Raymond James & Associates now owns 28,125 shares of the medical instruments supplier’s stock worth $1,596,000 after buying an additional 3,298 shares in the last quarter. Finally, Values First Advisors Inc. boosted its stake in shares of LeMaitre Vascular by 1.9% during the 4th quarter. Values First Advisors Inc. now owns 33,617 shares of the medical instruments supplier’s stock worth $1,908,000 after buying an additional 626 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.